TCTR20211026002招募中不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Hemodialysis Patients and Healthy Volunteers
Kao Tun Roke Foundation0 个研究点目标入组 130 人开始时间: 2021年10月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Adult (age >= 18 years old), 2.Hemodialysis patients, 3. Recipients 2 doses of ChAdOx1 nCoV-19 vaccine
排除标准
- •1. Refuse to participate, 2.Infected with COVID-19 during the study period, 3. Recipients of intravenous immunoglobulin
研究者
相似试验
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Kidney Transplant Recipients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in kidney transplant patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, kidney transplant patients, Wuhan Strain, B.1.617.2 (Delta) Variant, antibody, T-cell responseTCTR20211025004Kao Tun Roke Foundation200
已完成
不适用
Vaccination of kidney transplant and dialysis patients and their close household contacts against COVID-19Kidney TransplantDialysisRenal and Urogenital - Other renal and urogenital disordersACTRN12621000532808Central Adelaide Local Health Network176
招募中
不适用
To determine the safety and antibody performance in Indian adults after taking COVID-19 vaccine.CTRI/2021/03/031998Advanced Cancer for Treatment Research and Education in cancer and Tata Memorial Centre
已完成
4 期
Immunogenicity and safety of ChAdOx1 vaccine (Covid-19 vaccine) in Thai people with underlying diseaseDiabetes mellitusCirrhosissolid cancerHematologic malignancychronic kidney diseaserheumatological diseasecardiovascular diseaseChAdOx1 vaccineimmunogenicitycovid-19 vaccineTCTR20211228003Chulabhorn Royal Academy385
招募中
2 期
Immune response of booster dose with ChAdOx-1 in adult who had received 2 doses of CoronaVac (COVID-19)Prevention of COVID-19 with booster-dose strategy among healthy adult who received 2-dose of Coronavac using ChAdOx1 nCoV-19 vaccine.COVID-19 Vaccine, AstraZeneca Booster , Fractional low dose vaccineTCTR20210722003Health and Aging Platform, Chulalongkorn University400